The two sessions of the National People’s Congress will be held soon in 2022. The reporter of Securities Daily learned that Li Yan, deputy to the National People’s Congress and President of Qilu Pharmaceutical Group, put forward suggestions: further clarify the strategic position of the pharmaceutical industry at the national level, establish a complete policy support system, and take practical measures to support the innovation, upgrading and development of national pharmaceutical enterprises.
The pharmaceutical manufacturing industry is related to the national economy and the people’s livelihood and the long-term stability and sustainable development of the country. In recent years, the number of new drugs applied for clinical trials in China has increased significantly every year, the number of innovative drugs on the market has reached a record high, and the ability of enterprises to carry out international cooperation has been continuously enhanced. However, at the same time, China Meheco Group Co.Ltd(600056) manufacturing industry concentration is still low, the task of upgrading product structure is urgent, the innovation ability, especially the original innovation ability, is insufficient, and there are few high-quality innovation achievements. It is still in the stage of following and catching up with the United States and other advanced countries.
In order to promote China’s transformation from a “large pharmaceutical manufacturing country” to a “powerful pharmaceutical manufacturing country”, Li Yan suggested starting from the following aspects. At the national level, we should strengthen the systematicness, integrity and convergence of industrial planning, coordinate innovative resources and participate in the competition of international pharmaceutical industry. On the one hand, pay close attention to the implementation of the pharmaceutical industry planning. On the other hand, it is suggested to establish a “national team” for pharmaceutical industry innovation, concentrate China’s advantageous scientific research forces of pharmaceutical innovation, help promote and promote the speed and efficiency of China’s pharmaceutical innovation and R & D in different main directions, and participate in the competition of international pharmaceutical industry.
In terms of drug cooperative research and development, at present, the cooperation rate between original innovation projects of Chinese universities and enterprises is still low. Li Yan suggested to further optimize the integration mechanism of industry, University and research, accelerate the transformation of basic research results, and help the original innovation of national pharmaceutical industry. “Colleges and universities with outstanding R & D capabilities of common technologies and significant industrial technical service capabilities can apply for new scientific research institutes, allow researchers in the institutes to start businesses part-time, encourage the orderly flow of scientific and technological personnel, implement a green channel for professional title evaluation, attract more research and development talents to gather in school enterprise cooperation projects, and promote the industrialization and marketization of basic research.”
Under the background of increasing globalization of drug research and development, licensing transaction is an important means for pharmaceutical enterprises to rapidly expand product pipelines, and it is also an important step for Chinese enterprises to go international. However, there are still problems such as holder and site change in the follow-up industrialization policy. Li Yan suggested that in combination with the trend of China’s innovative drug introduction and foreign cooperation, continue to optimize the holder system, clarify that after the listing of drugs produced abroad, overseas holders are allowed to change to domestic holders, and clarify the registration path for the transfer of production sites from overseas to China, so as to realize the Chinese production of authorized introduction / cooperative development products as soon as possible, Better guarantee the supply of products urgently needed in clinic and facilitate supervision at the same time.
In the field of new drug research and development, Li Yan suggested setting a “traffic light” for capital, guiding capital convergence and supporting clinical value oriented drug research and development.
In recent years, with a large amount of capital entering the field of new drug R & D, innovative R & D has gradually entered a state of disorderly competition. In particular, the clinical trials of innovative drugs are deeply involved in homogenization, and innovative R & D is encouraged by “pulling out seedlings”. Li Yan said that the essence of capital is profit seeking, while drug R & D is typically characterized by a long cycle. There is a certain contradiction between the two. Short-term profit seeking behavior will curb real innovative R & D, which is not conducive to the sound development of China’s drug R & D in the long run.
“Set up a ‘traffic light’ for capital, match the ‘brake’ and then go on the road, guide capital to gather clinical value oriented drug R & D, more support source innovation, avoid short-term behavior of blindly chasing profits, return to the essence of innovation and R & D, and help the sustainable development of China’s drug innovation and R & D.” Li Yan said.
